TRC 694

Drug Profile

TRC 694

Alternative Names: JNJ-64290694

Latest Information Update: 09 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Janssen Pharmaceutica
  • Developer TRACON Pharmaceuticals
  • Class Antineoplastics
  • Mechanism of Action NF kappa B kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Haematological malignancies

Most Recent Events

  • 10 May 2017 TRACON announces intention to submit IND for TRC 694 by 2018
  • 01 Apr 2017 Pharmacodynamics data from a preclinical trial in Haematological malignancies presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 28 Sep 2016 Janssen Pharmaceutica and TRACON Pharmaceuticals enter options agreement for development of TRC 694
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top